Biotron Limited Overview
Biotron is a micro-capitalisation Australian drug-development company. For more than two decades it was a single-platform antiviral developer. Its scientific franchise is small-molecule antagonists of viroporins, the virus-encoded ion-channel proteins found across HIV-1, hepatitis viruses, coronaviruses, influenza and dengue. The flagship, BIT225, completed twelve clinical trials including three Phase 2 studies in 2023–24, but did not attract a licensing partner. The COVID-19 Phase 2 then missed its primary efficacy endpoint.
In December 2025 Biotron diversified by acquiring Sedarex Limited. Sedarex owns SedRx, a reformulated alfaxalone general anaesthetic that the company positions as a safer, cognition-sparing alternative to propofol, on an abbreviated European/US regulatory route.
Today Biotron is a virtual, outsourced R&D company with three platforms: an anaesthetic heading toward EMA engagement, a preclinical HBV/HDV candidate (BIT-HBV001), and the legacy BIT225 asset. It has no revenue, about A$1.55m in cash, a going-concern material uncertainty, and no CEO.
Company's own description.
Biotron describes its principal activity as funding and managing intermediate and applied biotechnology research and development projects (Annual Report FY2023, Directors' Report). Its core expertise is designing drugs against viroporins, the virus-encoded proteins that help viruses modulate and evade host immunity and sustain infection. It has built a library of compounds targeting viroporins across many human pathogens (Annual Report FY2023).
Since the Sedarex acquisition, the Group describes itself more broadly as focused on new treatments for serious diseases with unmet medical needs (1H FY2026 Interim Report, Note 1). The September 2026 investor presentation frames the company as a "diversified development portfolio." That portfolio comprises SedRx, a reformulated safer general anaesthetic, plus the antiviral pipeline led by BIT-HBV001.
Business model.
Biotron is a pure pre-revenue R&D company that follows a "develop-to-license" model:
-
It generates clinical and preclinical data to de-risk assets.
-
It then seeks to license or sell them to large pharmaceutical partners for late-stage development, registration and commercialisation.
The FY2023 annual report states that Phase 2 is generally the optimal licensing point. In late 2024 the company engaged US-based C14 Consulting Group LLC on a retainer-plus-success-fee basis to run partnering for the antiviral portfolio.
For SedRx, management has pointed to an abbreviated regulatory route that could bring it to market faster than a new chemical entity:
-
an FDA 505(b)(2) pathway in the US;
-
an abridged or hybrid procedure in Europe.
The July 2026 EMA feedback, however, complicated the Hybrid MAA route.
Revenue model mix.
Value-chain position.
Biotron sits at the discovery and early-clinical end of the pharmaceutical value chain. It owns no laboratories or manufacturing. It outsources compound synthesis, preclinical assays (for example, HBV mouse models and cell-based assays), clinical trials (CROs in Australia and Thailand) and regulatory work (an "international regulatory advisory group" for SedRx).
Customer types and end-markets.
Biotron has no commercial customers. Its prospective counterparties are:
-
global and specialty pharmaceutical companies, as licensees;
-
in the long term, hospitals and anaesthesia services (SedRx), hepatology and infectious-disease prescribers (HBV/HDV), and HIV clinics (BIT225).
Independent characterisation.
Biotron is a sub-A$10m "option value" biotech that has pivoted, by necessity, from a mature but un-partnered antiviral platform to an in-licensed, late-stage reformulation asset. The strategic logic is defensible. Alfaxalone is a known API, SBECD is an approved excipient, and the neurocognition angle in older surgical patients is topical.
Execution capacity, however, is the binding constraint:
-
cash covers only a few quarters at current burn;
-
the long-tenured CEO left in September 2026;
-
the board has been almost entirely replaced within twelve months.
Strategy
Stated strategic themes (paraphrased from FY2025–26 disclosures and the September 2026 presentation).
-
Diversify beyond antivirals through a late-stage, de-risked asset (SedRx) capable of near-term value generation (SmallCaps, Oct 2025; 1H FY2026 Interim Report).
-
Pursue abbreviated regulatory pathways: EMA abridged or hybrid route first, then FDA 505(b)(2) (1H FY2026; ASX 18 Mar 2026).
-
Extend SedRx patent life through a new neuroscience indication (SmallCaps, Oct 2025).
-
Advance BIT-HBV001 as a component of HBV "functional cure" combinations, broadened to HDV (ASX 18 Mar 2026).
-
Monetise BIT225 through partnering via C14 Consulting (1H FY2025 and 1H FY2026).
-
Match expenditure to available funding, a recurring going-concern commitment.
Initiatives announced in the last 24 months.
2026/27 milestones listed in the September 2026 investor presentation:
-
complete the proof-of-concept animal study for the new SedRx indication;
-
complete formal preclinical studies and synthesis for BIT-HBV001;
-
start a Phase 1 trial of BIT-HBV001, subject to funding.
ESG / sustainability commitments: none disclosed.
Medium-term financial targets / guidance: none provided. Management gives no revenue, earnings or cash guidance.
Products & Services
Biotron has no marketed products. Its catalogue is its development pipeline. Pricing models are not applicable or not disclosed for all assets.
SedRx (Sedarex Limited): next-generation intravenous general anaesthetic
Description. SedRx is a patented reformulation of alfaxalone, a neuroactive steroid anaesthetic. Alfaxalone was the active ingredient of Althesin, which according to Biotron was marketed in Europe for 14 years and held a 50% share of the UK day-care anaesthesia market (1H FY2026 Interim Report).
-
Althesin's original solvent, Cremophor EL, was linked to anaphylactic reactions.
-
SedRx replaces it with sulfobutyl ether beta-cyclodextrin (SBECD), an excipient already used in FDA- and EMA-approved products (SmallCaps, Oct 2025; March 2026 investor presentation).
Claimed capabilities.
-
Fast-onset, short-acting anaesthesia.
-
Superior safety and post-procedure cognitive outcomes versus leading anaesthetics in completed Phase 1 and pilot Phase 2a studies (described in presentations as a "pilot Phase 3 (2a)" comparison with propofol).
-
Potential relevance to populations at risk of post-anaesthetic neurocognitive impairment, such as older adults (Sharecafe, 13 Jul 2026; 1H FY2026 Interim Report).
Target customers. Hospitals, day-surgery and procedural-sedation settings. The emphasis is on elderly surgical patients.
Regulatory status.
-
Biotron has cited FDA backing for a 505(b)(2) pathway and a potentially abridged EMA approval (1H FY2026 Interim Report).
-
EMA scientific advice was received in July 2026 and satisfied acquisition Milestone 1.
-
That feedback indicated difficulties with a Hybrid Marketing Authorisation Application, because the reference product Althesin is unavailable for comparative bridging studies (June 2026 4C; InvestSMART summary of the 13 Jul 2026 announcement).
New indication. Sedarex is developing a new SedRx formulation for an undisclosed neuroscience indication. The second acquisition milestone is efficacy in an animal disease model, due by the earlier of nine months after product availability or December 2026 (1H FY2026 Note 17; September 2026 presentation).
Analyst note (unconfirmed linkage). An alfaxalone-in-SBECD formulation was previously developed by Melbourne-based Drawbridge Pharmaceuticals as "Phaxan" (Prof. Colin Goodchild, CMO):
-
Drawbridge founded 2011.
-
Patents granted in six countries in January 2014.
-
Phase 1c trial versus propofol (n=24) at Monash Health.
Biotron's March 2026 presentation cites Serrao and Goodchild research on alfaxalone and cognition. Biotron's filings do not, however, explicitly state the chain of title from Drawbridge/Phaxan to Sedarex/SedRx. This linkage is therefore flagged as unconfirmed.
BIT-HBV001: hepatitis B / hepatitis delta candidate
Description. BIT-HBV001 is a novel, undisclosed small-molecule viroporin-targeting compound, and Biotron's lead HBV candidate.
Key data (1H FY2026 Interim Report; ASX 18 Mar 2026).
-
Anti-HBV activity in two different HBV mouse models.
-
In cell-based assays, strong inhibition across five HBV replication endpoints, whereas tenofovir (first-line standard of care) was strongly active against only one.
-
Synergy with tenofovir in combination assays.
-
Inhibition of HDAg production in HBV/HDV co-infected cells, demonstrating anti-HDV activity.
Positioning. The company positions BIT-HBV001 as a candidate component of future functional-cure combination regimens.
Status and next steps.
-
Patent application filed in 1H FY2026, covering composition, manufacture and use.
-
Planned 2026/27 milestones: complete formal preclinical safety studies and synthesis, then start Phase 1, subject to funding (September 2026 investor presentation).
BIT225: first-in-class viroporin antagonist (HIV-1, SARS-CoV-2, HCV)
| Trial | Indication | Design | Outcome | Source |
|---|---|---|---|---|
| Phase Ib/IIa (FY2010) | HCV | First patient study | Successfully concluded | Appendix 4E FY2010 |
| BIT225-009 | HIV-1 | Phase 2 (prior) | Positive immunological effects (referenced) | Biotech Dispatch |
| BIT225-010 | HIV-1, treatment-naïve | Double-blind, placebo-controlled, 27 participants, Thailand, added to dolutegravir/TDF/FTC | Safe; faster second-phase plasma viral decay versus cART alone (preliminary) | Biotech Dispatch |
| BIT225-011 | HIV-1, immunological non-responders | Open-label, 20 participants, 200 mg daily for 12 weeks, Australia | Primary objectives met; no drug-related SAEs; changes in NK and T-regulatory cells; no CD4 increase | Stockhead; SmallCaps; BioWorld |
| BIT225-012 | COVID-19 | Double-blind, placebo-controlled, 60 participants, 200/400 mg for 7 days, Thailand | Primary safety endpoint met; primary efficacy endpoint missed; post-hoc Day 3–9 analysis p=0.02 | 1H FY2025 Interim Report |
Description. BIT225 is an oral small molecule that, per the company, combines direct-acting antiviral and immune-modulating activity. It targets the HIV-1 Vpu ion channel, among others.
Clinical history. According to the company, BIT225 has been through 12 completed clinical trials (1H FY2025 Interim Report).
Commercialisation. Partnering is being run with C14 Consulting Group (CEO Martina Molsbergen). No licence had been announced as at October 2026.
Discovery and earlier-stage programmes
Next-generation HIV-1 and SARS-CoV-2 compounds: lead optimisation (1H FY2025 Interim Report).
Dengue: subset of compounds tested against all four serotypes in cell assays (1H FY2025 Interim Report).
Influenza, Zika, RSV and others: library-level activity; influenza method-of-use patents granted in multiple jurisdictions (Annual Report FY2023).
Platform technology: bacterial cell-based screening assay for viroporin targets (Stockopedia/PatSnap company descriptions).
Financial Narrative
Basis of presentation.
-
All figures are in A$ thousands for fiscal years ended 30 June, unless stated otherwise.
-
FY2022–FY2023 come from the audited FY2023 Annual Report.
-
FY2024–FY2025 come from balance-sheet comparatives in the 1H FY2025 and 1H FY2026 interim reports, plus equity-reconciliation derivations (noted).
-
FY2026 uses the 4E summary (InvestSMART, Simply Wall St), the 4C reports and the 1H FY2026 accounts.
-
Biotron has no revenue, so gross profit, EBITDA margin and similar ratios are not meaningful (n/m).
Income statement
Notes to Table 6.1: Operating expenses: - FY2022–23: sum of audited expense lines.
-
FY2024–25: TipRanks (S&P-derived).
-
FY2026: Simply Wall St "other expenses" of about A$2.0m.
EBITDA: FY2022–23 is operating loss plus depreciation (A$45k and A$43k).
EPS: - FY2024: derived (A$3.437m divided by about 902m weighted shares).
-
FY2025: derived (A$0.319m divided by about 1.0bn weighted shares per TipRanks).
-
FY2026: analyst estimate. A$1.52m divided by an estimated 2.2bn weighted shares gives about -0.07 cents. The audited figure is n/d. InvestSMART displays -0.10 on a different basis.
FY2021 reference: net loss A$3,194,347; FY2020 A$3,575,959; FY2019 A$1,611,799 (Annual Report FY2023, remuneration-report table).
Revenue CAGR: n/m (zero revenue throughout).
Commentary.
Biotron's P&L is a pure function of R&D intensity offset by the refundable R&D Tax Incentive. Because the rebate is booked when received, it lags the spend that earned it by about one year.
FY2022–FY2024 (peak spending): losses of A$2.8–3.5m reflect the three-trial Phase 2 programme (BIT225-010, -011, -012). Direct R&D reached A$3.23m in FY2023, 64% of total expenses (KPMG Key Audit Matter, FY2023). 1H FY2024 alone carried A$2.20m of direct R&D.
FY2025 (near break-even): the loss fell to A$0.32m. Two forces drove this:
-
the large A$1.81m FY2024 rebate was recognised in 1H FY2025, producing a 1H profit of A$696,629;
-
the company cut R&D sharply after the COVID-19 trial missed (1H FY2025 direct R&D only A$315k), as its going-concern note required.
FY2026 (re-acceleration): the loss widened to about A$1.52m as the rebate fell to A$0.53m (reflecting FY2025's reduced R&D base), while costs rose with the Sedarex transaction, two capital raisings, EMA preparation and HBV animal studies. 1H FY2026 lost A$920,969, so 2H FY2026 was about A$0.6m.
Margins
The zeros above are placeholders only: every margin is not meaningful, because revenue is zero. A more useful measure is the rebate-coverage ratio (R&D Tax Incentive divided by total operating expenses). It was about 36% in FY2022, 28% in FY2023, 32% in FY2024, 84% in FY2025 and 26% in FY2026 (analyst calculation from Table 6.1).
Balance sheet
Notes to Table 6.3: Interim reference point (31 Dec 2025, 1H FY2026 report): - cash A$1,642,799; total assets A$3,860,304;
-
intangible assets A$2,129,791;
-
contingent consideration liability A$500,000;
-
total liabilities A$1,161,348; equity A$2,698,956; net current assets A$544,562.
FY2026 shares: shares at 30 Jun 2026 of 2,701,865,924 (derived). This rose to about 2,785m after the July 2026 milestone issue.
Debt: Biotron has no bank or bond debt. "Borrowings" are AASB 16 office-lease liabilities only.
Goodwill: nil. The acquisition was treated as an asset acquisition (no goodwill under AASB 3).
Commentary.
Recurring balance-sheet cycle: Cash is raised, then burned toward zero before the next raise. The low point was 30 June 2024, when equity was negative A$244,032 and working capital negative. The company was then dependent on the November 2024 A$1.81m rebate.
FY2025 repair: The year closed with A$0.93m of cash after a A$1.27m rights issue at A$0.003, with minimal R&D spend.
FY2026 balance-sheet change: The Sedarex acquisition added the first material non-cash asset in the company's history: SedRx IP carried at A$2.13m. That carrying value rests on share consideration valued at A$0.003 per share and on management's development assumptions.
Impairment risk: The July 2026 EMA feedback on the Hybrid MAA is a potential impairment indicator, if a full rather than hybrid dossier is required.
Cash flow
Notes to Table 6.4: FY2026 operating cash flow: sum of 1H FY2026 (-A$868,420, interim report), Mar-26 quarter (-A$686k, 4C) and Jun-26 quarter (-A$222k, 4C).
FY2026 capital raised: - placement A$1,000,000;
-
rights issue A$645,861;
-
shortfall A$878,733.
FY2026 acquired cash: A$111,513 of cash came with Sedarex (investing inflow).
-
The implied figure is about -A$3.5m to -A$3.6m (cash fell A$3.59m with negligible financing).
-
The implied figure is about -A$0.6m. 1H FY2025 was +A$489,468 because of the rebate.
Commentary. Cash burn tracks clinical activity:
FY2023–FY2024 (peak): about A$3.3–3.6m per year.
FY2025 (cost containment): about A$0.6m.
FY2026 (Sedarex integration and EMA work): about A$1.8m.
The two most recent quarters show gross operating burn of about A$0.7–0.75m per quarter, excluding the June 2026 rebate. Against A$1.55m of cash at 30 June 2026, the implied runway is roughly two quarters without new funding.
The 1H FY2026 going-concern note says cash-flow projections to 31 March 2027 depend on "significant additional funding." The company also has 289.3m listed options (exercise A$0.02, expiring 24 Nov 2027) plus 146.3m shortfall options. These are deep out of the money at A$0.002 and offer no realistic funding source unless the share price rises tenfold.
Ratios
Notes to Table 6.5: - These are analyst calculations from the balance sheets above.
-
ROE uses average equity. FY2021 opening equity was A$3,862,994.
-
FY2024 ROE is distorted by negative closing equity.
-
ROIC, net debt/EBITDA, interest coverage and the cash conversion cycle are not meaningful for a pre-revenue, debt-free company.
-
TipRanks shows a trailing ROE of -58% and ROA of -32% on a mixed-period basis. Discrepancies reflect averaging conventions.
Key financial inflections.
-
FY2023: A$6.0m raise funds the three Phase 2 trials.
-
FY2024: negative equity; COVID-19 trial failure follows in 2H CY2024.
-
FY2025: survival mode; rights issue at A$0.003 dilutes shareholders by about 47%.
-
FY2026: strategic pivot through the share-funded Sedarex purchase. The share count roughly doubles to about 2.7–2.8bn.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue from customers (AUD K) | 0 | 0 | 0 |
Other income: R&D Tax Incentive (AUD K) | 1,645 | 1,814 | 526 |
Segment pre-tax result (AUD K) | -3,437 | -319 | -1,520 |
Share of total revenue (%) | 0 | 0 | 0 |
Programme Unit Details
| Programme unit | Legal owner | Stage (Oct 2026) |
|---|---|---|
SedRx (anaesthesia/neuroscience) | Sedarex Limited | Phase 1 and pilot Phase 2a completed historically; EMA scientific advice received Jul 2026 |
BIT-HBV001 (HBV/HDV) | Biotron Limited | Preclinical (two mouse models, cell assays); Phase 1 subject to funding |
BIT225 (HIV-1, SARS-CoV-2, HCV) | Biotron Limited | Phase 2 completed; partnering via C14 |
Discovery library (dengue, influenza, others) | Biotron Limited | Early research |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from customers (AUD K) | 0 | 0 | 0 | 0 | 0 |
Other income: R&D Tax Incentive (AUD K) | 1,559 | 1,431 | 1,645 | 1,814 | 526 |
Direct R&D expense (AUD K) | 2,821 | 3,232 | — | — | — |
Employee and director expense (AUD K) | 882 | 919 | — | — | — |
Administration and consultants (AUD K) | 228 | 697 | — | — | — |
Total operating expenses (AUD K) | 4,338 | 5,039 | 5,110 | 2,150 | 2,000 |
Operating result before finance (AUD K) | -2,779 | -3,608 | — | — | — |
EBITDA (AUD K) | -2,734 | -3,565 | — | — | — |
Net finance income (AUD K) | -2 | 115 | — | — | — |
Pre-tax income = net income (AUD K) | -2,781 | -3,493 | -3,437 | -319 | -1,520 |
Basic/diluted EPS (A$ cents) | -0.40 | -0.43 | -0.38 | -0.03 | -0.07 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Financial Analysis
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 0 | 0 | 0 | 0 | 0 |
Operating margin (%) | 0 | 0 | 0 | 0 | 0 |
EBITDA margin (%) | 0 | 0 | 0 | 0 | 0 |
Net margin (%) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet and Share Count (millions)
| Metric (AUD K, at 30 June) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents | 1,741 | 3,984 | 393 | 932 | 1,554 |
Total current assets | 1,762 | 4,031 | 427 | 955 | — |
Intangible assets (SedRx IP) | 0 | 0 | 0 | 0 | — |
Total assets | 1,906 | 4,135 | 493 | 980 | — |
Total current liabilities | 751 | 956 | 738 | 429 | — |
Total liabilities | 814 | 962 | 738 | 429 | — |
Borrowings: short-term (lease) | 34 | 39 | 7 | 0 | 0 |
Borrowings: long-term (lease) | 43 | 7 | 0 | 0 | 0 |
Net debt (negative = net cash) | -1,664 | -3,939 | -386 | -932 | -1,554 |
Shareholders' equity | 1,092 | 3,173 | -244 | 552 | — |
Working capital | 1,012 | 3,076 | -311 | 527 | — |
Shares on issue (millions) | 702 | 902 | 902 | 1,327 | 2,702 |
Cash Flow
| Metric (AUD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | -2,436 | -3,290 | — | — | -1,776 |
Capital expenditure | 0 | 0 | 0 | -3 | 0 |
Free cash flow | -2,436 | -3,290 | — | — | -1,776 |
Gross equity raised | 0 | 6,001 | 20 | 1,281 | 2,525 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Net change in cash | -2,469 | 2,243 | -3,591 | 538 | 622 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | -112 | -164 | -235 | -207 | — |
ROA on year-end assets (%) | -146 | -84 | -697 | -33 | — |
ROIC (%) | n/m | n/m | n/m | n/m | n/m |
Current ratio (x) | 2.35 | 4.22 | 0.58 | 2.23 | — |
Debt/equity, lease liabilities only (x) | 0.07 | 0.01 | n/m | 0 | 0 |
Net debt/EBITDA (x) | n/m | n/m | n/m | n/m | n/m |
Interest coverage (x) | n/m | n/m | n/m | n/m | n/m |
Asset turnover (x) | 0 | 0 | 0 | 0 | 0 |
Cash conversion cycle (days) | n/m | n/m | n/m | n/m | n/m |
Geographic Revenue
| Region (revenue, AUD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia | 0 | 0 | 0 |
Americas | 0 | 0 | 0 |
EMEA | 0 | 0 | 0 |
Asia-Pacific ex-Australia | 0 | 0 | 0 |
Share Price
| Metric | Nov 2021 | Aug 2024 | Oct 2025 | Oct 2026 |
|---|---|---|---|---|
Share price (AUD) | 0.10 | 0.03 | 0.005 | 0.002 |
Change by Horizon
| Horizon | Change | Comment |
|---|---|---|
1-year | about -33% to -60% | Depends on base (A$0.003 pre-deal, A$0.005 intraday peak) |
3-year | about -95% | — |
5-year | about -98% | — |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
Market cap | ~A$5.6m | 2.79bn shares × A$0.002 |
Enterprise value | ~A$4.0m | Market cap less A$1.55m cash (30 Jun 2026); no debt |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | No sales |
P/B | ~2.1x | Against 31 Dec 2025 equity of A$2.70m; FY2026 book n/d |
EV / SedRx acquisition cost | ~1.9x | EV of A$4.0m versus A$2.1m paid; analyst metric |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | Never paid (FY2019–FY2026 tables show nil) |
Dividend policy | None; no franking credits |
Buybacks | None; no on-market buy-back (FY2023) |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | No borrowings. Only short-term payables and a A$0.5m contingent-consideration obligation (31 Dec 2025), settled in shares (A$250k converted July 2026; A$250k pending). |
Securities on Issue
| Security | Number | Terms |
|---|---|---|
Ordinary shares | ~2,785m | — |
Listed options (placement, rights and lead manager) | 289.3m | A$0.02 strike; expire 24 Nov 2027 |
Shortfall attaching options | 146.3m | A$0.02; expire Nov 2027 |
Performance shares (Sedarex Milestone 2) | 250,000 | Convert to A$250k of shares at VWAP (floor A$0.003) if milestone met by Dec 2026 |
Analyst Conclusions
Management guidance. There is no financial guidance. Operational milestones for 2026/27 (September 2026 presentation) are:
-
SedRx new-indication animal proof-of-concept (also Sedarex Milestone 2, due by December 2026).
-
Completion of BIT-HBV001 formal preclinical studies and synthesis.
-
Start of a BIT-HBV001 Phase 1 trial, subject to funding.
Consensus. None; there is no analyst coverage.
Bull case
-
Cheap option on a validated active ingredient. At about A$4m EV, the market prices SedRx at less than twice its acquisition cost. Yet SedRx carries human data versus propofol and potentially a 505(b)(2) route. A single US/EU partnering deal for a reformulated anaesthetic could re-rate the stock by multiples.
-
HBV/HDV optionality. BIT-HBV001 showed multi-endpoint superiority to tenofovir in vitro, synergy, activity in two mouse models and anti-HDV activity. These are characteristics that functional-cure combination developers seek, especially now that bepirovirsen has validated the category.
-
Refreshed, aligned board. The new board bought shares on market in July 2026, Milestone 1 was met on time, and the new chair has deep Sedarex knowledge. Together these suggest a credible path to a capital raise or partnering.
Bear case
-
Funding cliff. About A$1.55m of cash against about A$0.7m of gross quarterly burn implies a raise around 1H CY2027 at most. The likely price is at or below A$0.002, which means further heavy dilution, or a halt in development.
-
Regulatory reality check. The EMA feedback indicates the Hybrid MAA is impeded by the absence of Althesin, which could mean more clinical work and a longer, costlier path than the "near-term value" thesis implied at acquisition.
-
Leadership vacuum and track record. No licence followed 25 years of BIT225 development and three Phase 2 readouts. The CEO who led that work has left, and the board is three people.
Key catalysts and monitorables (next 12 months)
-
Appointment of a new CEO or MD; quality and incentive structure of the hire.
-
FY2026 Annual Report (around 16 Oct 2026). Watch the audited intangibles carrying value, impairment testing, going-concern wording and the remuneration report.
-
AGM (around November 2026): capacity resolutions (placement approvals) and board elections.
-
Sedarex Milestone 2 animal-efficacy result (by December 2026).
-
Release of the remaining Sedarex consideration shares from 12-month escrow (around December 2026).
-
Any capital raise: size, price, investor quality.
-
Any C14-sourced partnering transaction for BIT225 or the antiviral library.
-
The FY2026 R&D Tax Incentive refund, expected around 2H CY2026 on the higher FY2026 spend.
-
EMA/FDA follow-up meetings and a defined SedRx clinical plan.
-
BIT-HBV001 IND/CTA-enabling progress.
Analyst verdict
Biotron Limited is, in substance, a reconstituted micro-cap biotech. For two decades it was a single-mechanism antiviral company, under the long stewardship of Chairman Michael Hoy and Managing Director Michelle Miller. That company produced an extensive but commercially unrewarded data package for BIT225. The decisive failure of the BIT225-012 COVID-19 Phase 2 to meet its primary efficacy endpoint in 2024 effectively closed the "partner after Phase 2" thesis. It left the company with negative equity in mid-2024 and no realistic funding route other than deeply discounted rights issues.
The December 2025 acquisition of Sedarex was a rational response. For A$2.1m in shares, Biotron acquired an anaesthetic built on a known active ingredient and an approved excipient, with human comparative data against propofol and a plausible abbreviated regulatory route. Milestone 1 was delivered on schedule in July 2026. The accompanying EMA feedback, however, exposed a structural problem with the hybrid pathway: the reference product no longer exists.
Within nine months of the acquisition, the original leadership had fully exited. Biotron is now controlled in practice by a three-person board led by the former Sedarex chair, with no chief executive and about two quarters of cash. The equity is a low-priced, high-variance option. The upside is a partnering transaction or a clearly costed SedRx registration plan, paired with a credible CEO appointment. The downside is further dilution at or below A$0.002, or a pause in development.
On the evidence available, Biotron is a speculative, binary, funding-constrained situation. The next three events will largely determine whether the SedRx thesis survives:
-
the CEO appointment;
-
the terms of the next capital raise;
-
the Milestone 2 animal-efficacy readout (due December 2026).
Absent progress on all three, the base case is continued dilution.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Age |
|---|---|---|---|---|
Dr Paul A. Kasian, BSc (Hons), PhD (Microbiology), MBA, GAICD | Non-Executive Chairman (Chair from May 2026) | Director 23 Dec 2025 | Former Executive Chairman of Sedarex Ltd, Genetic Technologies Ltd and Zucero Therapeutics; former NED and Audit and Risk Chair at Atomo Diagnostics; former Chairman of IODM; former CIO at HSBC Asset Management Australia; current Chairman of Diamond Key International. Sedarex nominee under the acquisition terms. | — |
Michael J. Medway, BBus, CA | Independent Non-Executive Director | 16 Jul 2025 | Chartered Accountant for 30+ years; director of Maas Group Holdings (ASX: MGH) since its 2020 IPO; BBus (Accountancy), University of Technology Sydney | — |
Dr Graeme Wald | Non-Executive Director | 30 Mar 2026 | Investment Director at BioScience Managers; Partner in OneVentures Fund III; previously a director of a company through its NASDAQ listing | 63 (MarketScreener) |
Managing Director / CEO | Vacant | — | Search under way since 14 Sep 2026 | — |
Marcelo Mora, BBus, GradDip Applied Corporate Governance | Company Secretary | 2 May 2025 | Accountant and Chartered Secretary for 30+ years | 62 (MarketScreener) |
Board of Directors (2)
| Name | Former role | Tenure | Departure |
|---|---|---|---|
Dr Michelle Miller, BSc, MSc, PhD, GCertAppFin | Managing Director and CEO | 21 Jun 2002 – 14 Sep 2026 | Resigned for personal reasons; remains available to assist the transition. Previously at Johnson & Johnson (anti-HIV gene therapeutics) and an investment manager at a bioscience VC fund. |
Michael J. Hoy | Chairman | Director from 7 Feb 2000; Chair from 16 Mar 2000 | Retired 15 May 2026 |
Robert B. Thomas, BEc, FICD | Independent NED | 7 Mar 2012 – 6 Feb 2026 | Retired; chairman of Starpharma |
Dr Susan M. Pond AM | Independent NED | 7 Mar 2012 – 28 Nov 2024 | Retired; former chair and MD of J&J Research Australia |
Prof. Stephen Locarnini | Independent NED | 23 Oct 2018 – 28 Nov 2024 | Retired; HBV authority, ex-WHO regional reference laboratory director |
Peter J. Nightingale | Company Secretary | 23 Feb 1999 – 2 May 2025 | Replaced by M. Mora |
Directors' Remuneration
| Name | Year | Fees/salary (AUD) | Superannuation (AUD) | Share-based (AUD) | Other (AUD) | Total (AUD) |
|---|---|---|---|---|---|---|
Michelle Miller (MD) | FY2023 | 341,457 | 35,853 | 0 | 10,117 | 387,427 |
Michelle Miller (MD) | FY2022 | 328,766 | 32,877 | 10,585 | 8,211 | 380,439 |
Michael Hoy (Chair) | FY2023 | 75,000 | 7,875 | 0 | 0 | 82,875 |
Susan Pond (NED) | FY2023 | 40,000 | 4,200 | 0 | 0 | 44,200 |
Robert Thomas (NED) | FY2023 | 40,000 | 4,200 | 0 | 0 | 44,200 |
Stephen Locarnini (NED) | FY2023 | 40,000 | 4,200 | 0 | 0 | 44,200 |
Peter Nightingale (Co. Sec.) | FY2023 | 120,000 | 0 | 0 | 0 | 120,000 |
Major Shareholders
| Holder | Shares | Approx. % of about 2.79bn | Date / source |
|---|---|---|---|
Sedarex vendors (aggregate consideration shares) | 583,333,333 | 20.9 | 500m issued Dec 2025 plus 83.3m issued Jul 2026 (1H FY2026; Sharecafe); individual holdings n/d; escrow released 29 May 2026 (225.2m) and Dec 2026 (remainder, 12-month escrow) |
Peak Asset Management (facilitation shares) | 33,333,333 | 1.2 | 1H FY2026 Note 17 |
Dr Graeme Wald (indirect) | 16,276,333 | 0.6 | On-market purchase 13 Jul 2026 (InvestSMART). Simply Wall St lists one independent NED at about 2.71%. |
Dr Paul Kasian (indirect) | 12,189,000 | 0.4 | On-market purchase 13 Jul 2026 (InvestSMART); total holding n/d |
Dr Michelle Miller (direct and super fund) | 10,100,000 | 0.4 | Appendix 3Z, 14 Sep 2026 (5.3m direct plus 4.8m indirect; plus 1.26m listed options) |
Competitive Landscape
Competitors by Segment
| Arena | Competitor | Asset / approach | Status relevant to Biotron |
|---|---|---|---|
HBV functional cure | GSK / Ionis | Bepirovirsen (Hibsago), antisense oligonucleotide | Approved in Japan 24 Aug 2026 as first functional-cure CHB therapy; 19% functional cure in B-Well Phase 3; FDA priority review and Breakthrough designation (GSK 6-K Aug 2026; AJMC May 2026) |
HBV standard of care | Gilead Sciences | Tenofovir alafenamide (Vemlidy), tenofovir DF | Chronic suppressive therapy; Biotron benchmarks against tenofovir |
HDV | Gilead Sciences | Bulevirtide (Hepcludex) | — |
HBV/HDV | Vir Biotechnology | siRNA plus monoclonal antibody combinations | — |
HBV | Arbutus Biopharma | Imdusiran (RNAi) | — |
HBV | Aligos Therapeutics; Assembly Biosciences | Capsid modulators and others | — |
HIV-1 | Gilead Sciences | Integrase-based single tablets; lenacapavir | Dominant market share; 2024 lenacapavir PrEP data highly effective (BioWorld, Jun 2024) |
HIV-1 | ViiV Healthcare (GSK/Pfizer/Shionogi) | Dolutegravir-based regimens, long-acting injectables | Major competitor |
IV anaesthesia | Fresenius Kabi, Baxter and other generic manufacturers | Propofol (generic) | Entrenched, low-cost standard of care |
IV sedation / anaesthesia | Remimazolam marketers (e.g., Byfavo licensees) | Ultra-short-acting benzodiazepine | — |
Veterinary alfaxalone | Jurox / Zoetis (Alfaxan) | Alfaxalone in cyclodextrin (veterinary) | — |
ASX micro-cap biotech peers | Peers named by S&P/Simply Wall St (e.g., ASX: VIT, CMB, EPN) | Various | Competitors for scarce retail biotech capital |
Competitor Detail
| Metric | Biotron (FY2026) |
|---|---|
Revenue | A$0 |
Revenue growth | n/m |
Operating margin | n/m |
R&D intensity | n/m (R&D about 60%+ of expenses) |
Market cap | ~A$5.6m |
Recent Developments
--



